Liver Cancer Survival: How Should We Interpret It in 2026?

South Korea's 5-year relative survival rate for liver cancer is 40.4% (National Cancer Registration Statistics, 2019–2023), but this is a nationwide average, and an individual's course can vary significantly depending on liver function and cancer stage.

Key Takeaways

• South Korea's 5-year relative survival rate for liver cancer is 40.4% (National Cancer Registration Statistics, 2019–2023, Central Cancer Registry, National Cancer Center Korea).
• For reference, the U.S. SEER 5-year relative survival rate for liver and intrahepatic bile duct cancer is 21.9% (SEER 2016–2022). Both figures are nationwide statistics, not results from any specific hospital.
• Survival rates are population averages and do not predict any individual's outcome. Even at the same stage, the course of disease can vary greatly depending on liver function grade (Child-Pugh) and portal pressure.
• Treatment goals and options for liver cancer differ by stage: early stage (resection, ablation, transplantation), intermediate stage (embolization), and advanced stage (systemic drug therapy).
• South Korea runs a national screening program offering ultrasound and blood tests every 6 months for hepatitis B carriers and cirrhosis patients, which contributes to a relatively high rate of detection at small tumor sizes.

How many years can someone survive with liver cancer?

• Short answer: Nationally in South Korea, the overall 5-year relative survival rate is 40.4% (National Cancer Registration Statistics, 2019–2023), but this is a national average combining all stages and is not a number that predicts an individual's course.
• This figure comes from nationwide statistics compiled by the Central Cancer Registry at the National Cancer Center Korea, not from any single hospital's treatment outcomes. By comparison, the U.S. SEER (2016–2022) 5-year relative survival rate for liver and intrahepatic bile duct cancer is 21.9%; differences in screening systems and early-detection rates between the two countries affect these numbers.
• Liver cancer is a disease in which the range of available treatments and prognosis are determined not only by cancer stage but also by liver function grade (Child-Pugh), portal pressure, and overall physical condition. Even tumors of the same size may call for different treatments depending on liver function.

How does treatment progress by stage?

• Stage 1, very early/early stage (small tumors, few in number, good liver function): liver resection is the first choice; if resection is not feasible, radiofrequency ablation is considered; if liver function has declined but tumor size and number are within criteria, liver transplantation is reviewed.
• Stage 2, intermediate stage (multiple tumors within the liver): transarterial chemoembolization (TACE) is the mainstay, sometimes combined with radioembolization, stereotactic radiotherapy (SBRT), or particle therapy.
• Stage 3, advanced stage (vascular invasion or spread outside the liver): systemic drug therapy becomes central. Combinations of immune checkpoint inhibitors and anti-angiogenic agents are included in first-line standard treatment, and oral targeted therapies may be used depending on the case. At this stage, the realistic goal is described as tumor control and extending survival rather than cure.
• Stage 4, when liver function has significantly declined: chemotherapy may further damage the liver, so the focus shifts to symptom control, preserving liver function, and reviewing the possibility of transplantation.

FAQ — Can stage 4 (advanced) liver cancer be cured?

For advanced-stage liver cancer, the goal is generally described not as 'cure' but as tumor control and symptom management through systemic drug therapy. Unlike the term 'remission' used as a standard in blood cancers, this is not a standardized term; depending on treatment response, slowing disease progression is explained as the realistic goal. However, outcomes can vary greatly from person to person depending on liver function, portal pressure, and the number and location of tumors.

FAQ — Can I apply this survival rate directly to my own case?

No. The 40.4% figure is a nationwide statistic from South Korea's National Cancer Registration Statistics (2019–2023) covering all stages combined, not the outcome of any specific hospital. Survival rates are group averages; individual outcomes may differ depending on stage, liver function grade (Child-Pugh), hepatitis control status, and treatment response. Treatment direction should always be determined through consultation with your medical team.

Sources and Notes

• This article was written based on the National Cancer Registration Statistics 2019–2023 (Central Cancer Registry, National Cancer Center Korea), SEER 2016–2022, the National Cancer Information Center, and explanations at the level of NCCN patient guidelines.
• This content is intended for general medical information purposes only. Diagnosis, treatment methods, and outcomes may vary depending on individual circumstances. Accurate diagnosis and treatment must always be determined through consultation with your medical team.